OncoGenex Pharmaceuticals, Inc. (OGXI) Down 9% on Disappointing Phase 3 ENSPIRIT Trial Results
OncoGenex Pharmaceuticals (NASDAQ: OGXI) shares slid more than 9% in Thursday’s mid-day trade following the company’s morning announcement that its phase 3 ENSPIRIT trial of custirsen in patients whose non-small cell lung cancer (NSCLC) did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with docetaxel compared to docetaxel alone. Safety results were consistent with those observed in previous trials of custirsen in combination with chemotherapy. To view the full press release, visit: http://nnw.fm/X5x4V About OncoGenex OncoGenex is a biopharmaceutical company committed to the development and commercialization of…







